Ex vivo quantification of anti-tumor T-cell activity upon anti-PD-1 treatment in patient-derived lung tumor-on-chip

Irina Veith,Arianna Mencattini,Martin Nurmik,Isabelle Damei,Christine Lansche,Solenn Brosseau,Giacomo Gropplero,Stéphanie Corgnac,Joanna Filippi,Nicolas Poté,Pierre Mordant,Jimela Tosello,Christine Sedlik,Eliane Piaggio,Nicolas Girard,Jacques Camonis,Hamasseh Shirvani,Fathia Mami-Chouaib,Fatima Mechta-Grigoriou,Stéphanie Descroix,Eugenio Martinelli,Gérard Zalcman,Maria Carla Parrini

DOI: https://doi.org/10.1101/2023.06.21.545960

2023-06-22

Abstract:ABSTRACT There is a compelling need for new approaches to predict efficacy of immunotherapy drugs. Tumor-on-chip technology exploits microfluidics to generate 3D cell co-cultures embedded in hydrogels that recapitulate immune and stromal characteristics of a simplified tumor ecosystem. Here, we present the development and validation of lung-tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune check-point inhibitors on T-cell-mediated cancer cell death, by exploiting the power of live imaging and advanced image analysis algorithms. These tumor-on-chips were generated with patient-derived autologous primary cells isolated from fresh lung cancer samples, opening the path for applications in personalized medicine. Moreover, cancer-associated fibroblasts were shown to impair the response to anti-PD-1, indicating that tumor-on-chips are capable of recapitulating stroma-dependent mechanisms of immunotherapy resistance. This interdisciplinary combination of microfluidic devices, clinically-relevant cell models, and advanced computational methods, can innovatively improve both the fundamental understanding and clinical efficacy of immuno-oncology drugs.